Tag Archives: Andrew Dillon

Guest Blogspot – The UK Government’s Latest Thinking on the Value-Based Pricing of Medicines

The UK Government yesterday published its detailed response to the three-month public consultation concluded in March 2011 on value-based pharmaceutical pricing. The Government has emphasised that work on the proposals is still at an early stage. The mistake made with … Continue reading

Posted in Andrew Lansley, Business, Department of Health, Drugs, Employment, Finance, Innovation, NHS, Patients, Pharma, Policy, Research | Tagged , , , , , , , , , , , , , , , , , , , , , , | Leave a comment